Isaac Francis

Monash IVF Group (ASX:MVF) revised its financial outlook for 2026, forecasting an underlying net profit after tax of between $17 million and $18 million.

Bitcoin surged to a multi-day high of $63,700 while oil prices tumbled below $87 after US President Donald Trump announced that planned military strikes against Iran had been cancelled.

Beetaloo Energy (ASX:BTL) flagged a mid-June commencement for its critical Carpentaria-5H extended production test.

C4 Therapeutics (NASDAQ:CCCC) reported updated clinical data from its Phase 1 trial evaluating cemsidomide, an investigational oral molecular glue degrader targeting IKZF1/3, for the treatment of relapsed or refractory multiple myeloma.

Silence Therapeutics (NASDAQ:SLN) reported positive follow-up and quality-of-life clinical data for its experimental blood cancer treatment, divesiran, demonstrating a sustained reduction in the medical procedures required to manage the rare disease.

Takeda Pharmaceutical (NYSE:TAK) reported positive topline results from a head-to-head Phase 3 clinical trial for its experimental plaque psoriasis drug, zasocitinib, positioning the oral pill to challenge established autoimmune blockbusters.

Modiv Industrial (NYSE:MDV) announced the declaration of its scheduled cash distributions for both preferred and common shareholders, maintaining capital returns as the real estate investment trust prepares for its upcoming corporate combination.

Vertex Pharmaceuticals (NASDAQ:VRTX) announced highly anticipated clinical data demonstrating that its CRISPR-based gene-editing therapy, CASGEVY, matches its highly successful adult profile when used in younger children.

Ripple chief executive Brad Garlinghouse has endorsed claims that Wall Street firms and crypto companies are increasingly adopting the institutional finance strategy that XRP and Ripple promoted years ago.

Bitget Wallet's tokenised SpaceX IPO subscription sold out within 30 minutes after attracting US$13 million in commitments, underscoring growing demand for blockchain-based access to high-profile equity offerings.